Mode
Text Size
Log in / Sign up
N/A N=39 Randomized Treatment

Comparison of Endotracheal Intubation Over the Aintree Via the I-gel and Laryngeal Mask Airway Supreme

Difficult Intubation

Enrolled (actual)
39
Serious AEs
0.0%
Results posted
Jan 2018
Primary outcome: Primary: Time to Successful Tracheal Intubation — 197; 304 seconds

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
LMA-Supreme supraglottic device (Device); I-gel supraglottic device (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Vanderbilt University
Primary completion
Sep 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to Successful Tracheal Intubation
197; 304
SECONDARY
Time to Placement of the Supra Glottic Device
155; 301
SECONDARY
Percent of Subjects Who Required 0, 1, 2, and 3 Airway Manipulations for the Placement of the Supraglottic Device
80; 80; 10; 13; 5; 7
SECONDARY
Time to Placement of the Aintree Airway Intubation Catheter
155; 301
SECONDARY
Percent of Subjects Who Required 0, 1, 2, 3 and 6 Airway Manipulations for the Placement of the Aintree.
67; 25; 33; 25; 0; 31
SECONDARY
Time to Placement of the Endotrotracheal Tube
81; 96
SECONDARY
Percent of Subjects With 0, 1, 2 and 3 Airway Manipulations Required for Placement of Endotrachial Tube
67; 57; 17; 43; 11; 0

Summary

The investigators plan to conduct a randomized trial comparing the efficacy of intubating the tracheal using an Aintree intubation catheter through either the LMA-S or I-gel supraglottic devices

Eligibility Criteria

Inclusion Criteria

  • Subjects that will require routine endotracheal intubation for general anesthesia as part of their surgery.
  • Age >18 years old.
  • Can provide informed consent.

Exclusion Criteria

  • Subjects that require rapid sequence induction for endotracheal intubation; i.e., parturients, or any subject that is at high risk for aspirating gastric contents into the airway.
  • Subjects that have an allergy to Propofol or eggs.
  • Subjects that have an allergy to rocuronium.
  • Subjects with a history of oropharyngeal or laryngeal surgery, or subjects undergoing oropharyngeal or laryngeal surgery.
  • Subjects with congenital or anatomical airway anomalies.
  • Subjects with anticipated reduced functional residual capacity as predicted by a body mass index ≥40.
  • Currently enrolled in another research study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02476565). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search